|Bid||20.16 x 800|
|Ask||20.99 x 900|
|Day's Range||19.77 - 20.92|
|52 Week Range||13.67 - 27.80|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||23.04|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.46|
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The latter is a scrappy biotech stock that has found ways to survive, despite setbacks, for more than 25 years. Regardless of previous success, investing is about the future. DNA sequencer products, like Illumina's, allow scientists to determine the information and instructions carried by a DNA sample.
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.